Long-Term Results of Wegovy: ​​Latest Findings from the SELECT Trial!

Video will be live on Monday, July 8 at 1:00 PM Central Time. 

▪️ Join my channel to get access to perks! 
▪️ Download my FREE 7-Day Best Weight Journal here.  
▪️ Subscribe to my YouTube channel here.   

A recent study published in May 2024 unveiled a long-term outcome of Semaglutide, known as Wegovy or Ozempic. This builds on the SELECT trial, which showed Wegovy could reduce major cardiovascular events by 20% in individuals with obesity and no diabetes. Conducted by Ryan et al., the study followed participants for 208 weeks, or about four years.

The primary finding was not a new side effect but a continuation of Wegovy’s benefits. Participants experienced an average weight loss of about 10%, maintained over the entire four-year period. Initially, participants lost weight until around week 65, then sustained this weight reduction for the remainder of the study.

The results are impressive. The weight loss was not just temporary but sustained throughout the study’s duration. This stability contrasts with other long-term studies, such as those with Saxenda, where there is a tendency for weight regain over time. Wegovy’s ability to maintain weight loss over four years underscores its potential as a long-term weight management solution.

Regarding actual side effects, the study found no new or alarming issues. There were no new cases of cancers or other unusual conditions. About 17% of participants stopped taking Wegovy due to gastrointestinal side effects, aligning with other studies of GLP-1 medications. This finding supports the overall safety and effectiveness of Wegovy for long-term use.

In summary, this research highlights that the long-term “side effect” of Wegovy is a continued benefit: sustained weight loss over four years. This study reinforces the drug’s role in effective and durable weight management.

Thanks for watching and always remember: small tweaks lead to massive peaks! 

References: Ryan, D.H., Lingvay, I., Deanfield, J. et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-02996-7

Don’t forget to hit the subscribe button for more insightful content, and consider joining our YouTube Members Membership for exclusive benefits and monthly live sessions. 

Watch my previous videos to learn how to fight obesity and about the best medicine for weight loss: 
▪️ Watch This Before Taking Mounjaro  
▪️ From Ozempic to Mounjaro 
▪️ Muscle Loss with Ozempic, Wegovy & Mounjaro 
▪️ Managing Nausea from Ozempic, Wegovy and Trulicity!  
▪️ Ozempic: Stomach Paralysis Update  
▪️ How to Switch from Ozempic (or Wegovy) to Mounjaro  
▪️ Ozempic Paralyzed My Stomach 
▪️ How to Inject Mounjaro: step-by-step tutorial

Live in Alberta? Come see me at my Pharmacist-led Obesity Clinic at Apothecare Pharmacy – http://apothecarerx.ca 

Products I recommend to support your weight-loss journey: 
▪️ Managing Constipation 
▪️ Managing Diarrhea 
▪️ Managing Heartburn 
▪️ Internalized Weight Bias 
▪️ Protein Bars
▪️ Scales and More 
▪️ Supplements 
▪️ Activity Trackers  
▪️ My favorite Books 

– 

Dr. Dan

Follow me on social media for regular updates – @TheOfficialDrDan

Subscribe to my newsletter for a heads-up on all new content.

Sharing is caring! Here’s the social, email, and even text link –
https://healthevolved.co/long-term-wegovy

If you need some coaching support on your weight management journey, you can book a consultation with me to see if you’d be a good fit for our program. 

Questions or comments? Please send them my way on our Contact Us page!

Share:

More Posts

The Ozempic Pill Has a Ceiling — New Trial Proves It

New clinical trial data on orforglipron reveals a biological ceiling that every person on GLP-1 medications needs to understand. I’m breaking down the ATTAIN-MAINTAIN trial findings, explaining what the 15% threshold means for long-term weight management, and identifying exactly who is — and isn’t — a strong candidate for the transition to the Ozempic pill.

Reducing Your Zebound Dose Could Undo ALL Your Progress

The SURMOUNT MAINTAIN trial has delivered the most compelling evidence yet that obesity requires long-term management — not a finish line. New data reveals exactly what happens to your results at every dose decision, and the numbers make the choice undeniable.

The Retatrutide Paradox: Why This “Triple Threat” Works

Retatrutide is a triple-action therapy targeting GLP-1, GIP, and glucagon receptors simultaneously — a fundamentally different design from current treatments. Early clinical data reveals significant liver-fat reductions and an unexpected paradox: a receptor long assumed to raise blood sugar instead helps mobilize stored fat and support resting metabolism.

Retatrutide TRIUMPH-1 Results: 28% Weight Loss

TRIUMPH-1 Phase 3 trial data reveals retatrutide achieved up to 30% body weight loss — outperforming bariatric surgery benchmarks without a single incision. I’m breaking down the full efficacy numbers, safety signals, and what this triple-hormone agonist means for your weight management options right now.

Send Us A Message

Try My New Calorie Calculator!

Calculate your daily calorie and protein targets to help you achieve your weight goals.

Try My New Calorie Calculator!

Calculate your daily calorie and protein targets to help you achieve your weight goals.